Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces a share repurchase program. Under the program, the company will repurchase up to CNY 1,200 million worth of its shares. The shares will be purchased at a price not exceeding CNY 67.38 per share.

The repurchased shares will be used for the implementation of ESOP or equity incentive plan; to convert the company's convertible bonds; to maintain the company's value and shareholders' rights and interests; to reduce registered capital. The program will be funded from company's own funds. The program will be valid for 12 months.